Trial Information
A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium
Inclusion Criteria:
- adult patients =/<18 years of age
- metastatic colorectal cancer
- patients for whom the physician has prescribed bevacizumab [Avastin] for the
treatment of 1st line metastatic colorectal cancer
- patients, who have given written informed consent
Exclusion Criteria:
- hypersensitivity to recombinant human or humanised antibodies
- pregnancy or breast-feeding
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Observation of treatment duration in daily clinical practice
Outcome Time Frame:
Throughout study, approximately 34 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Belgium: Federal Agency for Medicinal Products and Health Products
Study ID:
ML25117
NCT ID:
NCT01089413
Start Date:
January 2010
Completion Date:
June 2013
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms